MT-3921 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 26 | HTLV-1関連脊髄症 | 1 |
26. HTLV-1関連脊髄症
臨床試験数 : 28 / 薬物数 : 48 - (DrugBank : 28) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05240612 (ClinicalTrials.gov) | March 2022 | 13/2/2022 | A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) | A Clinical Pharmacological Study of MT-3921 in Subjects With Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM) | HTLV-1-Associated Myelopathy (HAM) | Biological: MT-3921;Biological: Placebo | Mitsubishi Tanabe Pharma Corporation | NULL | Not yet recruiting | 20 Years | N/A | All | 15 | Phase 1 | NULL |